Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062.
作者:
主题词
成年人(Adult);老年人(Aged);蒽环类(Anthracyclines);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);癌, 非小细胞肺(Carcinoma, Non-Small-Cell Lung);顺铂(Cisplatin);无病生存(Disease-Free Survival);依托泊甙(Etoposide);欧洲(Europe);女(雌)性(Female);人类(Humans);肺肿瘤(Lung Neoplasms);男(雄)性(Male);中年人(Middle Aged);存活率分析(Survival Analysis);存活率(Survival Rate);时间因素(Time Factors);治疗结果(Treatment Outcome)
DOI
10.1016/j.ejca.2011.05.020
PMID
21684151
发布时间
2013-11-21
- 浏览50
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文